董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Peter Hebert | 男 | Chairman | 43 | 未披露 | 未持股 | 2022-01-14 |
| Josh DeFonzo | 男 | Chief Executive Officer and Director | 39 | 未披露 | 未持股 | 2022-01-14 |
| Joseph Robert Kerrey | 男 | Director | 76 | 未披露 | 未持股 | 2022-01-14 |
| Fred Moll | 男 | Director | 68 | 未披露 | 未持股 | 2022-01-14 |
| Bijan Salehizadeh | 男 | Director | 47 | 未披露 | 未持股 | 2022-01-14 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Josh DeFonzo | 男 | Chief Executive Officer and Director | 39 | 未披露 | 未持股 | 2022-01-14 |
| Segolene Scarborough | 女 | Chief Financial Officer and Treasurer | 41 | 未披露 | 未持股 | 2022-01-14 |
董事简历
中英对照 | 中文 | 英文- Peter Hebert
-
Peter Hebert，2008年6月他担任我们董事会成员。他是Lux Capital公司（一家风险投资公司，他于2000年联合创立）的管理合伙人。除了Everspin之外，他担任Auris Surgical Robotics, Inc.、Gridco Inc.、Lux Research, Inc.、Halo Neuro, Inc.、Flex Logix Technologies, Inc.和Matterport, Inc.的董事会职务。从2003年到2008年，他担任Lux Research的创始首席执行官，他帮助构建为一个主要新兴技术研究公司。在Lux Research任职期间，他启动来Lux Nanotech Index和the PowerShares Lux Nanotech Portfolio的上市。他获得Syracuse University的学士学位，他以优异成绩从the S.I. Newhouse School of Public Communications毕业。
Peter Hebert has been our Chairman since inception. Mr. Hébert is Co-Founder and Managing Partner of Lux Capital, a $2.4 billion venture capital firm based in New York, NY and Menlo Park, CA. Peter led Lux's investments in Auris Health acquired by Johnson & Johnson for up to $5.75 billion, including consideration of milestone payments, Lux Research (acquired by Private Equity), Luxtera (acquired by Cisco for $660 million), SiBEAM (acquired by Silicon Image) and Vium (acquired by Recursion Pharma). Current investments include Avail, Bright Machines, Everspin Technologies (NASDAQ: MRAM), Flex Logix, Matterport, Ripcord and Transphorm. In 2003 Peter led the spin-off of Lux Research. As its founding CEO, he helped build Lux Research into a leading emerging-technology research firm. Peter began his career at Lehman Brothers, where he worked in the firm's top-ranked Equity Research group. He was a Chancellor's Scholar and graduated cum laude from Syracuse University's Newhouse School and was the Founding President of its first venture organization, Future Business Leaders and Entrepreneurs. He has been a guest on CNBC and Bloomberg TV and speaker at Columbia, Cornell, MIT, Stanford, Yale and the National Science Foundation. Mr. Peter Hébert is a co-founder and managing partner of Lux and oversees Lux's investments at the intersection of technology and medical devices, including Auris Health, which was acquired by Johnson & Johnson and Avail Medsystems. - Peter Hebert，2008年6月他担任我们董事会成员。他是Lux Capital公司（一家风险投资公司，他于2000年联合创立）的管理合伙人。除了Everspin之外，他担任Auris Surgical Robotics, Inc.、Gridco Inc.、Lux Research, Inc.、Halo Neuro, Inc.、Flex Logix Technologies, Inc.和Matterport, Inc.的董事会职务。从2003年到2008年，他担任Lux Research的创始首席执行官，他帮助构建为一个主要新兴技术研究公司。在Lux Research任职期间，他启动来Lux Nanotech Index和the PowerShares Lux Nanotech Portfolio的上市。他获得Syracuse University的学士学位，他以优异成绩从the S.I. Newhouse School of Public Communications毕业。
- Peter Hebert has been our Chairman since inception. Mr. Hébert is Co-Founder and Managing Partner of Lux Capital, a $2.4 billion venture capital firm based in New York, NY and Menlo Park, CA. Peter led Lux's investments in Auris Health acquired by Johnson & Johnson for up to $5.75 billion, including consideration of milestone payments, Lux Research (acquired by Private Equity), Luxtera (acquired by Cisco for $660 million), SiBEAM (acquired by Silicon Image) and Vium (acquired by Recursion Pharma). Current investments include Avail, Bright Machines, Everspin Technologies (NASDAQ: MRAM), Flex Logix, Matterport, Ripcord and Transphorm. In 2003 Peter led the spin-off of Lux Research. As its founding CEO, he helped build Lux Research into a leading emerging-technology research firm. Peter began his career at Lehman Brothers, where he worked in the firm's top-ranked Equity Research group. He was a Chancellor's Scholar and graduated cum laude from Syracuse University's Newhouse School and was the Founding President of its first venture organization, Future Business Leaders and Entrepreneurs. He has been a guest on CNBC and Bloomberg TV and speaker at Columbia, Cornell, MIT, Stanford, Yale and the National Science Foundation. Mr. Peter Hébert is a co-founder and managing partner of Lux and oversees Lux's investments at the intersection of technology and medical devices, including Auris Health, which was acquired by Johnson & Johnson and Avail Medsystems.
- Josh DeFonzo
-
Josh DeFonzo，自公司成立起担任公司首席执行官和董事。DeFonzo先生自2003年以来一直在医疗保健技术行业工作。他在各种专业和疾病状态下商业化和开发医疗设备、诊断和生物制剂。Josh的职业生涯始于任职Medtronic，作为一家精品分销商，他将广泛的技术商业化，并在产品和执行管理方面为硅谷的几家医疗保健技术初创公司做出了贡献，包括被Stryker收购的Invuity，Endogastic Solutions，CareDx（纳斯达克市场代码:CDNA）和最近的Auris Health（2019年4月被强生公司以高达57.5亿美元的价格收购，其中包括里程碑付款）。Josh在加州大学伯克利分校获得经济学学士学位。
Josh DeFonzo has been our Chief Executive Officer and a director since inception. Mr. DeFonzo has been in the healthcare technology industry since 2003. He has commercialized and developed medical devices, diagnostics and biologics across a variety of specialties and disease states. Josh began his career with Medtronic, commercialized a wide range of technology as a boutique distributor and has contributed, in product and executive management capacities, to several healthcare technology startups in Silicon Valley including Invuity acquired by Stryker, EndoGastric Solutions, CareDx (NASDAQ: CDNA) and most recently Auris Health (acquired by Johnson & Johnson in April 2019 for up to $5.75 billion, including consideration of milestone payments). Josh received a B.A. in Economics from the University of California, Berkeley. - Josh DeFonzo，自公司成立起担任公司首席执行官和董事。DeFonzo先生自2003年以来一直在医疗保健技术行业工作。他在各种专业和疾病状态下商业化和开发医疗设备、诊断和生物制剂。Josh的职业生涯始于任职Medtronic，作为一家精品分销商，他将广泛的技术商业化，并在产品和执行管理方面为硅谷的几家医疗保健技术初创公司做出了贡献，包括被Stryker收购的Invuity，Endogastic Solutions，CareDx（纳斯达克市场代码:CDNA）和最近的Auris Health（2019年4月被强生公司以高达57.5亿美元的价格收购，其中包括里程碑付款）。Josh在加州大学伯克利分校获得经济学学士学位。
- Josh DeFonzo has been our Chief Executive Officer and a director since inception. Mr. DeFonzo has been in the healthcare technology industry since 2003. He has commercialized and developed medical devices, diagnostics and biologics across a variety of specialties and disease states. Josh began his career with Medtronic, commercialized a wide range of technology as a boutique distributor and has contributed, in product and executive management capacities, to several healthcare technology startups in Silicon Valley including Invuity acquired by Stryker, EndoGastric Solutions, CareDx (NASDAQ: CDNA) and most recently Auris Health (acquired by Johnson & Johnson in April 2019 for up to $5.75 billion, including consideration of milestone payments). Josh received a B.A. in Economics from the University of California, Berkeley.
- Joseph Robert Kerrey
-
Joseph Robert Kerrey自2020年10月以来一直担任我们的董事之一。Senator Kerrey自2014年起担任投资银行公司Allen&Company的董事总经理。此前，他曾担任the New School的总裁（从2001年1月到2011年1月）。从1988年到2000年，他担任内布拉斯加州的美国参议员。在此期间，他是许多国会特许委员会和参议院委员会的成员，包括参议院财政和拨款委员会以及参议院情报特别委员会。在此之前，他从1982年到1987年担任内布拉斯加州州长。Senator Kerrey也是Tenet 医疗保健Corporation的首席董事，在那里他自2012年以来担任董事，是三个私人公司的董事会成员:Imagen，Intarcia和Monolith Energy。他也是Auris Health公司的前董事会成员。
Joseph Robert Kerrey has served as one of our directors since October 2020. Senator Kerrey has served as a managing director of Allen & Company, an investment banking firm, since 2014. Prior to this he served as President of the New School from January 2001 to January 2011. From 1988 to 2000 he served as U.S. Senator from Nebraska. During that period, he was a member of numerous congressionally chartered commissions and Senate committees, including the Senate Finance and Appropriations Committees and the Senate Select Committee on Intelligence. Prior to that time, he served as Governor of Nebraska from 1982 to 1987. Senator Kerrey is also the lead director of Tenet Healthcare Corporation, where he has served as a director since 2012 and is a board member of three private companies: Imagen, Intarcia, and Monolith Energy. He is also a former member of the board of directors of Auris Health. - Joseph Robert Kerrey自2020年10月以来一直担任我们的董事之一。Senator Kerrey自2014年起担任投资银行公司Allen&Company的董事总经理。此前，他曾担任the New School的总裁（从2001年1月到2011年1月）。从1988年到2000年，他担任内布拉斯加州的美国参议员。在此期间，他是许多国会特许委员会和参议院委员会的成员，包括参议院财政和拨款委员会以及参议院情报特别委员会。在此之前，他从1982年到1987年担任内布拉斯加州州长。Senator Kerrey也是Tenet 医疗保健Corporation的首席董事，在那里他自2012年以来担任董事，是三个私人公司的董事会成员:Imagen，Intarcia和Monolith Energy。他也是Auris Health公司的前董事会成员。
- Joseph Robert Kerrey has served as one of our directors since October 2020. Senator Kerrey has served as a managing director of Allen & Company, an investment banking firm, since 2014. Prior to this he served as President of the New School from January 2001 to January 2011. From 1988 to 2000 he served as U.S. Senator from Nebraska. During that period, he was a member of numerous congressionally chartered commissions and Senate committees, including the Senate Finance and Appropriations Committees and the Senate Select Committee on Intelligence. Prior to that time, he served as Governor of Nebraska from 1982 to 1987. Senator Kerrey is also the lead director of Tenet Healthcare Corporation, where he has served as a director since 2012 and is a board member of three private companies: Imagen, Intarcia, and Monolith Energy. He is also a former member of the board of directors of Auris Health.
- Fred Moll
-
Fred Moll自2020年10月以来一直担任我们的董事之一。Moll博士自2011年起担任Shockwave Medical董事会成员。自2019年4月以来，Moll博士一直担任强生公司医疗设备公司的首席发展官。Moll博士也是联合Founder，自2012年9月起担任Auris Health的董事长兼首席执行官。Moll博士曾于2002年11月担任Restoration Robotics的董事兼董事会主席，直到2019年11月与Venus Concept合并。从2002年到2010年，他曾担任Hansen Medical公司（他也是该公司的共同创始人）的首席执行官。此前，Moll博士联合创立了Intuitive Surgical，并从1995年到1998年担任其第一任首席执行官。Moll博士还共同创立了Endo-Therapeutics和Origin MedSystems，该公司后来被Eli Lilly&Company收购，成为Guidant Corporation的运营公司。Moll博士是Intersectent的董事会成员。Moll博士在加州大学伯克利分校获得经济学学士学位，在斯坦福大学获得管理学硕士学位，在华盛顿大学获得医学博士学位。
Fred Moll has served as one of our directors since October 2020. Dr. Moll has served as a member of the Shockwave Medical board of directors since 2011. Since April 2019 Dr. Moll has served as Chief Development Officer for Johnson & Johnson Medical Device Companies. Dr. Moll is also a co-founder, and, since September 2012 has been the Chairman and Chief Executive Officer of Auris Health. Dr. Moll previously served as a director and as Chairman of the board of Restoration Robotics from November 2002 until its merger with Venus Concept in November 2019. From 2002 to 2010 Dr. Moll served as the Chief Executive Officer of Hansen Medical, which he also co-founded. Previously, Dr. Moll co-founded Intuitive Surgical and from 1995 to 1998 served as its first Chief Executive Officer. Dr. Moll also co-founded Endo-Therapeutics, and Origin MedSystems, which later became an operating company within Guidant Corporation following its acquisition by Eli Lilly & Company. Dr. Moll serves on the board of directors of IntersectENT. Dr. Moll received a B.A. in economics from the University of California at Berkeley, an M.S. in management from Stanford University and an M.D. from the University of Washington. - Fred Moll自2020年10月以来一直担任我们的董事之一。Moll博士自2011年起担任Shockwave Medical董事会成员。自2019年4月以来，Moll博士一直担任强生公司医疗设备公司的首席发展官。Moll博士也是联合Founder，自2012年9月起担任Auris Health的董事长兼首席执行官。Moll博士曾于2002年11月担任Restoration Robotics的董事兼董事会主席，直到2019年11月与Venus Concept合并。从2002年到2010年，他曾担任Hansen Medical公司（他也是该公司的共同创始人）的首席执行官。此前，Moll博士联合创立了Intuitive Surgical，并从1995年到1998年担任其第一任首席执行官。Moll博士还共同创立了Endo-Therapeutics和Origin MedSystems，该公司后来被Eli Lilly&Company收购，成为Guidant Corporation的运营公司。Moll博士是Intersectent的董事会成员。Moll博士在加州大学伯克利分校获得经济学学士学位，在斯坦福大学获得管理学硕士学位，在华盛顿大学获得医学博士学位。
- Fred Moll has served as one of our directors since October 2020. Dr. Moll has served as a member of the Shockwave Medical board of directors since 2011. Since April 2019 Dr. Moll has served as Chief Development Officer for Johnson & Johnson Medical Device Companies. Dr. Moll is also a co-founder, and, since September 2012 has been the Chairman and Chief Executive Officer of Auris Health. Dr. Moll previously served as a director and as Chairman of the board of Restoration Robotics from November 2002 until its merger with Venus Concept in November 2019. From 2002 to 2010 Dr. Moll served as the Chief Executive Officer of Hansen Medical, which he also co-founded. Previously, Dr. Moll co-founded Intuitive Surgical and from 1995 to 1998 served as its first Chief Executive Officer. Dr. Moll also co-founded Endo-Therapeutics, and Origin MedSystems, which later became an operating company within Guidant Corporation following its acquisition by Eli Lilly & Company. Dr. Moll serves on the board of directors of IntersectENT. Dr. Moll received a B.A. in economics from the University of California at Berkeley, an M.S. in management from Stanford University and an M.D. from the University of Washington.
- Bijan Salehizadeh
-
2007年8月以来，Bijan Salehizadeh一直是我们董事。他目前担任 NaviMed Capital Advisors LLC联合创始人和运营总监，这是一家私人投资公司，专注于成长创业投资医疗保健投资。他也作为Highland Capital Partners LLC顾问，这是一家风险投资公司。从2004年9月至2011年8月，他是Highland Capital Partners投资专家，在那里他最近担任普通合伙人。 他专注于医疗保健的投资，主要是在医疗产品，医疗服务和生物制药公司。在此从事医疗保健投资前，他曾在Medtronic 和 HealthCentral任多个职位。 他目前担任多个私人医疗保健公司董事。 他获得了哥伦比亚大学医学博士和硕士学位，获得哈佛商学院MBA以及 普林斯顿大学分子生物学学士学位。
Bijan Salehizadeh, M.D. has been a member of our Board since August 2007. Dr. Salehizadeh currently serves as co-founder and Managing Director at NaviMed Capital Advisors LLC, a private investment firm focused on growth venture capital healthcare investments. Dr. Salehizadeh also serves as an advisor to Highland Capital Partners LLC, a venture capital firm. From September 2004 to August 2011 Dr. Salehizadeh was an investment professional at Highland Capital Partners, where he most recently served as General Partner. Dr. Salehizadeh focused on healthcare investments, primarily in medical products, healthcare services, and biopharmaceutical companies. Prior to healthcare investing, Dr. Salehizadeh served in various positions at Medtronic and HealthCentral. Dr. Salehizadeh currently serves on the board of directors of several private healthcare companies. Dr. Salehizadeh received an M.D. and an M.S. in Health Policy from Columbia University, an M.B.A. from Harvard Business School and an A.B. in Molecular Biology from Princeton University. - 2007年8月以来，Bijan Salehizadeh一直是我们董事。他目前担任 NaviMed Capital Advisors LLC联合创始人和运营总监，这是一家私人投资公司，专注于成长创业投资医疗保健投资。他也作为Highland Capital Partners LLC顾问，这是一家风险投资公司。从2004年9月至2011年8月，他是Highland Capital Partners投资专家，在那里他最近担任普通合伙人。 他专注于医疗保健的投资，主要是在医疗产品，医疗服务和生物制药公司。在此从事医疗保健投资前，他曾在Medtronic 和 HealthCentral任多个职位。 他目前担任多个私人医疗保健公司董事。 他获得了哥伦比亚大学医学博士和硕士学位，获得哈佛商学院MBA以及 普林斯顿大学分子生物学学士学位。
- Bijan Salehizadeh, M.D. has been a member of our Board since August 2007. Dr. Salehizadeh currently serves as co-founder and Managing Director at NaviMed Capital Advisors LLC, a private investment firm focused on growth venture capital healthcare investments. Dr. Salehizadeh also serves as an advisor to Highland Capital Partners LLC, a venture capital firm. From September 2004 to August 2011 Dr. Salehizadeh was an investment professional at Highland Capital Partners, where he most recently served as General Partner. Dr. Salehizadeh focused on healthcare investments, primarily in medical products, healthcare services, and biopharmaceutical companies. Prior to healthcare investing, Dr. Salehizadeh served in various positions at Medtronic and HealthCentral. Dr. Salehizadeh currently serves on the board of directors of several private healthcare companies. Dr. Salehizadeh received an M.D. and an M.S. in Health Policy from Columbia University, an M.B.A. from Harvard Business School and an A.B. in Molecular Biology from Princeton University.
高管简历
中英对照 | 中文 | 英文- Josh DeFonzo
Josh DeFonzo，自公司成立起担任公司首席执行官和董事。DeFonzo先生自2003年以来一直在医疗保健技术行业工作。他在各种专业和疾病状态下商业化和开发医疗设备、诊断和生物制剂。Josh的职业生涯始于任职Medtronic，作为一家精品分销商，他将广泛的技术商业化，并在产品和执行管理方面为硅谷的几家医疗保健技术初创公司做出了贡献，包括被Stryker收购的Invuity，Endogastic Solutions，CareDx（纳斯达克市场代码:CDNA）和最近的Auris Health（2019年4月被强生公司以高达57.5亿美元的价格收购，其中包括里程碑付款）。Josh在加州大学伯克利分校获得经济学学士学位。
Josh DeFonzo has been our Chief Executive Officer and a director since inception. Mr. DeFonzo has been in the healthcare technology industry since 2003. He has commercialized and developed medical devices, diagnostics and biologics across a variety of specialties and disease states. Josh began his career with Medtronic, commercialized a wide range of technology as a boutique distributor and has contributed, in product and executive management capacities, to several healthcare technology startups in Silicon Valley including Invuity acquired by Stryker, EndoGastric Solutions, CareDx (NASDAQ: CDNA) and most recently Auris Health (acquired by Johnson & Johnson in April 2019 for up to $5.75 billion, including consideration of milestone payments). Josh received a B.A. in Economics from the University of California, Berkeley.- Josh DeFonzo，自公司成立起担任公司首席执行官和董事。DeFonzo先生自2003年以来一直在医疗保健技术行业工作。他在各种专业和疾病状态下商业化和开发医疗设备、诊断和生物制剂。Josh的职业生涯始于任职Medtronic，作为一家精品分销商，他将广泛的技术商业化，并在产品和执行管理方面为硅谷的几家医疗保健技术初创公司做出了贡献，包括被Stryker收购的Invuity，Endogastic Solutions，CareDx（纳斯达克市场代码:CDNA）和最近的Auris Health（2019年4月被强生公司以高达57.5亿美元的价格收购，其中包括里程碑付款）。Josh在加州大学伯克利分校获得经济学学士学位。
- Josh DeFonzo has been our Chief Executive Officer and a director since inception. Mr. DeFonzo has been in the healthcare technology industry since 2003. He has commercialized and developed medical devices, diagnostics and biologics across a variety of specialties and disease states. Josh began his career with Medtronic, commercialized a wide range of technology as a boutique distributor and has contributed, in product and executive management capacities, to several healthcare technology startups in Silicon Valley including Invuity acquired by Stryker, EndoGastric Solutions, CareDx (NASDAQ: CDNA) and most recently Auris Health (acquired by Johnson & Johnson in April 2019 for up to $5.75 billion, including consideration of milestone payments). Josh received a B.A. in Economics from the University of California, Berkeley.
- Segolene Scarborough
Segolene Scarborough自公司成立以来一直是我们的首席财务官兼财务主管。Scarborough女士是Lux Capital的首席财务官，并领导所有财务业务，包括有限合伙人报告，管理季度关闭，年度审计和税务报告。她也是Lux Portfolio Companies的资源，为行业基准和建立有效的财务团队提供战略顾问。在2017年加入Lux之前，Segolene是Sequoia Capital的财务总监，该公司是一家风险投资公司，总部位于加利福尼亚州门洛帕克，她于2013年6月在那里开始工作。在那里，她负责LP报告，融资，投资组合公司估值以及月度和季度结算。此前，她曾任职PricewaterhouseCoopers公司（位于比利时布鲁塞尔和加利福尼亚州圣何塞），从事财务审计，专注于生物技术和风险资本。
Segolene Scarborough has been our Chief Financial Officer and Treasurer since inception. Ms. Scarborough is CFO and leads all financial operations at Lux Capital, including limited partner reporting, managing quarterly closes, annual audit and tax reporting. She is also a resource for Lux portfolio companies, providing strategic counsel on industry benchmarks and building effective finance teams. Prior to joining Lux in 2017 Segolene was Controller at Sequoia Capital, a venture capital firm headquartered in Menlo Park, CA, where she started in June of 2013. While there, she was responsible for LP reporting, financings, portfolio company valuations and monthly and quarterly closes. She previously worked in financial audit at PricewaterhouseCoopers in Brussels, Belgium and San Jose, California focusing on biotech and venture capital.- Segolene Scarborough自公司成立以来一直是我们的首席财务官兼财务主管。Scarborough女士是Lux Capital的首席财务官，并领导所有财务业务，包括有限合伙人报告，管理季度关闭，年度审计和税务报告。她也是Lux Portfolio Companies的资源，为行业基准和建立有效的财务团队提供战略顾问。在2017年加入Lux之前，Segolene是Sequoia Capital的财务总监，该公司是一家风险投资公司，总部位于加利福尼亚州门洛帕克，她于2013年6月在那里开始工作。在那里，她负责LP报告，融资，投资组合公司估值以及月度和季度结算。此前，她曾任职PricewaterhouseCoopers公司（位于比利时布鲁塞尔和加利福尼亚州圣何塞），从事财务审计，专注于生物技术和风险资本。
- Segolene Scarborough has been our Chief Financial Officer and Treasurer since inception. Ms. Scarborough is CFO and leads all financial operations at Lux Capital, including limited partner reporting, managing quarterly closes, annual audit and tax reporting. She is also a resource for Lux portfolio companies, providing strategic counsel on industry benchmarks and building effective finance teams. Prior to joining Lux in 2017 Segolene was Controller at Sequoia Capital, a venture capital firm headquartered in Menlo Park, CA, where she started in June of 2013. While there, she was responsible for LP reporting, financings, portfolio company valuations and monthly and quarterly closes. She previously worked in financial audit at PricewaterhouseCoopers in Brussels, Belgium and San Jose, California focusing on biotech and venture capital.